Evidence map›Paper›PMID 42734649›Full record

ArticleVirchows Archiv : an international journal of pathology2026

OGT-rearranged mesenchymal neoplasm of the palm with a novel C3orf62/MAPS partner gene: expanding the molecular spectrum of this rare entity.

Federico Repetto, Klaus J Busam, Arivarasan Karunamurthy, Mohamed Yakoub, Konstantinos Linos

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Federico RepettoDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, USA.
Klaus J BusamDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Arivarasan KarunamurthyDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Mohamed YakoubDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Konstantinos LinosDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. linosk@mskcc.org.ORCID http://orcid.org/0000-0001-9462-652X

Funding

Memorial Sloan-Kettering Cancer Center MSK NIH/NCI Cancer Center Support Grant P30 CA008748
6 · The paper itself

Abstract

OGT-rearranged mesenchymal neoplasm is a rare, molecularly defined soft tissue tumor with an acral predilection and recurrent fusions involving FOXO1, FOXO3, FOXO4, or CITED1. We report a tumor of the left ulnar palm in a 72-year-old woman presenting as a scaly papule. Shave biopsy demonstrated a bland dermal mesenchymal neoplasm composed of epithelioid to spindled cells arranged in cords and small nests within a hyalinized to fibromyxoid stroma. The lesional cells expressed CD34 diffusely and EMA focally, whereas SOX10 and SMA were negative. Targeted RNA sequencing identified a novel in-frame OGT::C3orf62/MAPS fusion joining OGT exon 22 to MAPS exon 3 and predicted to preserve the OGT enzymatic architecture. MAPS is implicated in phase separation and chromatin organization. This case expands the molecular and clinical spectrum of OGT-rearranged mesenchymal neoplasm, documents C3orf62/MAPS as a novel fusion partner, and highlights its dermal papular presentation as a potential diagnostic pitfall in routine dermatopathology.

Indexed as

Acral soft tissue tumorC3orf62MAPSMyoepithelioma-like hyalinizing epithelioid tumorOGTRNA sequencing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.